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Standard measurement methods from the resting ECG trace define quantitative ECG measurements PR inter-
val, QRS axis, QRS duration, and QTc interval (QT interval 
corrected for heart rate) that predict cardiovascular morbid-
ity and mortality.1–3 These traits predict risk of arrhythmias 
and sudden death, particularly where there is prolongation of 
QTc or of QRS durations.4 PR interval, QRS axis, QRS dura-
tion, and QTc interval reflect a system of anatomically com-
partmented electrophysiological events and characteristics 
underpinned by voltage-gated ion channels, together acting 
in a cyclical fashion. Cardiac P wave represents atrial depo-
larization, QRS complex represents ventricular depolariza-
tion, and QTc interval represents ventricular repolarization. 
Some of these electrocardiographic traits have a significant 
genetic basis,5 with a wide diversity of rare mutations in 
more than 20 genes known to have monogenic effects on 
these traits and predispose to arrhythmia (online-only Data 
Supplement Table I). 
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Background—Electrocardiographic traits are important, substantially heritable determinants of risk of arrhythmias and sudden 
cardiac death.
Methods and Results—In this study, 3 population-based cohorts (n=10 526) genotyped with the Illumina HumanCVD Beadchip 
and 4 quantitative electrocardiographic traits (PR interval, QRS axis, QRS duration, and QTc interval) were evaluated for single-
nucleotide polymorphism associations. Six gene regions contained single nucleotide polymorphisms associated with these traits 
at P<10−6, including SCN5A (PR interval and QRS duration), CAV1-CAV2 locus (PR interval), CDKN1A (QRS duration), 
NOS1AP, KCNH2, and KCNQ1 (QTc interval). Expression quantitative trait loci analyses of top associated single-nucleotide 
polymorphisms were undertaken in human heart and aortic tissues. NOS1AP, SCN5A, IGFBP3, CYP2C9, and CAV1 showed 
evidence of differential allelic expression. We modeled the effects of ion channel activity on electrocardiographic parameters, 
estimating the change in gene expression that would account for our observed associations, thus relating epidemiological 
observations and expression quantitative trait loci data to a systems model of the ECG.
Conclusions—These association results replicate and refine the mapping of previous genome-wide association study findings for 
electrocardiographic traits, while the expression analysis and modeling approaches offer supporting evidence for a functional 
role of some of these loci in cardiac excitation/conduction. (Circ Cardiovasc Genet. 2012;5:630-638.)
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Less is understood of the contributions of common genetic 
variations that underpin population variation in these electro-
cardiographic traits. Recent genome-wide association studies 
(GWAS) have identified associated genomic regions, although 
the causal variants (or even genes) usually remain unknown 
from these analyses. The most widely replicated gene from 
these studies is NO synthase 1 (neuronal) adaptor protein 
(NOS1AP),6–10 but the identity and number of functional single-
nucleotide polymorphisms (SNPs) in this gene remain unre-
solved. Following GWAS with SNP replication, it is proposed 
that gene-centric SNP panels that more densely capture the 
genetic architecture for specific loci, as well as represent-
ing important candidate genes, may help to refine association 
 signals within candidate genes and also permit follow-up in 
a wider variety of cohorts and traits.11 For cardiovascular risk 
genes, the Illumina HumanCVD BeadChip was constructed 
for this purpose.11 In this study, we describe a meta-analysis of 
PR interval, QRS axis, QRS duration, and QTc interval using 
HumanCVD BeadChip data for 3 cohorts (n=10 526). For each 
of the main loci identified, we model the genotypic difference 
in gene expression that would be consistent with the phenotypic 
effects observed in our analysis. Ultimately, a systems model 
should be able to integrate genotypic, expression, conductance, 
electrophysiological, and clinical data.
Materials and Methods
Study Cohorts
Association analyses were carried out using 10 526 participants from 
3 population-based cohorts: British Women’s Heart and Health Study 
(BWHHS), Genetic Regulation of Arterial Pressure of Humans in 
the Community (GRAPHIC), and the Whitehall II Study. Full details 
of these cohorts and collection of ECG data and blood samples for 
genetic analyses are presented in the online-only Data Supplement 
Materials and Methods.
Electrocardiographic Measures
Standard 12 lead ECGs were recorded on either Siemens 460 electro-
cardiographs (Camberley, Surrey, UK) or Burdick Eclipse (Manchester, 
UK) or Atria (Manchester, UK) models. Digital ECG data were trans-
ferred to the University of Glasgow ECG Core Lab at Glasgow Royal 
Infirmary and analyzed by the University of Glasgow ECG analysis pro-
gram.12,13 This software meets all of the required specifications in terms 
of measurement accuracy and is used widely in various commercial 
products. All ECGs were reviewed manually, and technically unsatisfac-
tory ECGs were excluded (eg, reversed limb lead connections, excessive 
artifact, etc). The measurements used in this study were: PR interval, 
QRS axis, QRS duration, and QTc interval (corrected for heart rate 
 using the Hodges equation: QTc=QT+1.75×[RATE−60] ms).14 Outliers 
>3 SDs from the mean in each study were excluded from the analysis.
Genotyping and Quality Control
All 3 cohorts used the Illumina HumanCVD BeadArray (Illumina Inc, 
San Diego, CA), which comprises ≈50 000 SNPs in ≈2100 genes sys-
tematically selected as cardiovascular disease candidates by an interna-
tional consortium.11 Genotypes were called using Illumina BeadStudio 
(v3) Genotyping Module (based on GenCall application, which incor-
porates the GenTrain clustering algorithm). Samples with genotype 
call rate <90% were removed from the analysis. SNPs were included 
in the association analysis if they satisfied the following criteria: SNP 
call rate ≥0.95, minor allele frequency >1%, and Hardy-Weinberg 
Equilibrium P>1×10−4. Based on HumanCVD principal components 
analysis, there is no evidence for significant population stratification in 
these 3 cohorts (this finding is consistent with self-reported ancestry).
SNP Association Analyses
Separate within-cohort linear regression analyses (n=3 cohorts) were 
performed for each trait using an additive genetic model  relating the 
trait to genotype dosage (0–2 copies of the minor allele) for each SNP, 
adjusting for age, sex, body mass index, and systolic blood pressure 
(after correction for antihypertensive medication).15 Covariates were 
selected based on prior knowledge of physiological measurements af-
fecting the ECG. In GRAPHIC, additional adjustment for age (using 
age2 because of the 2 generational structure of the cohort) and famil-
ial correlation (using Generalized Estimating Equations with an ex-
changeable correlation structure) was made to take into account the 
family structure. After verifying strand alignment, a meta-analysis of 
the results from the 3 studies was conducted using a fixed-effects mod-
el. A comparison with a random-effects model (DerSimonian-Laird)16 
was also performed and showed similar results. Heterogeneity (mea-
sured using I2 17) was variable between SNPs. We adopted a P value 
threshold of 1×10−5 for the reporting of putative associations but only 
discuss those with a P value below 1×10−6 in detail. The 1×10−5 thresh-
old represents a trade-off between maintaining a low false-positive rate 
and taking into account the higher prior odds of association that a se-
lected, gene-centric  approach offers over unbiased GWAS,11 as SNPs 
represented on the array were selected based on prior knowledge of 
cardiovascular disease loci. Based on a linkage disequilibrium (LD) 
cut-off of r2=0.2 in Whitehall II, there are ≈19 000 independent SNPs in 
the HumanCVD array. A Bonferroni correction based on 19 000 SNPs 
gives a P=0.05 equivalent of P=2.6×10−6. Association results between 
these 2 thresholds (1×10−6<P<1×10−5) should be interpreted with cau-
tion but are included for information. At each locus with >1 significant-
ly associated SNP, an adjusted association analysis was performed to 
identify independent effects from the lead SNPs. For each locus identi-
fied, the lead SNP was added to the regression model as a covariate to 
identify additional SNPs that passed our significance threshold.
Expression Quantitative Trait Loci Analysis
The Advanced Study of Aortic Pathology (ASAP) consisted of 
patients undergoing aortic valve and aorta replacement surgery at 
the Karolinska University Hospital, Stockholm, Sweden.18 In this 
study, samples from heart (needle biopsy of left ventricle), aorta 
intima-media, and aorta adventitia were investigated. Altogether 399 
samples from 215 different patients were included. RNA was extracted 
as described by Folkersen et al18 and hybridized onto Affymetrix 
GeneChip Human Exon 1.0 ST expression arrays to determine gene 
expression levels. Cel files were preprocessed in Affymetrix Power 
Tools (1.10.2) and normalized using Robust Multichip Average 
Normalization19 (with measurements log2 transformed as part of this 
process). The preprocessing and analysis are described in reference 
18. DNA samples from ASAP patients were genotyped using Illumina 
Human 610 W-Quad Beadarrays and imputed using the MACH 
algorithm20 and data from the 1000 genomes project.
All SNPs associated with electrocardiographic traits at P<1×10−5 were 
investigated for expression quantitative trait loci (eQTL) effects with the 
closest gene and fold-change of gene expression per minor allele esti-
mated using an additive linear model, that is, values >1 indicate increased 
expression with the minor allele of an SNP, and values <1 indicate de-
creased expression with the minor allele of an SNP. A false discovery rate 
of 5% for the 21 reported tests corresponds to an uncorrected P≤0.00532.
Integrative Modeling
We applied an established model of electrical action potentials of human 
ventricular cells (see reference 21 for description and validation of this 
model) to simulate conduction of excitation wave across the transmural 
strand of human ventricle.22 The algorithm of Shaw and Rudy23 was used 
to simulate the effects of changes of ion channel expression or activity on 
electrocardiographic parameters. We used our data except for SCN10A, 
KCNE1, and KCNJ, which were not represented in HumanCVD 
BeadChip; for these we used the replication datasets as in references24 
and 9. We modeled the effects of changes of ion channel expression on 
QRS duration and QTc interval but did not model PR interval as the 
model lacks consideration of atria. Eight distinct ion currents influenc-
ing the cardiac action potential25 and hence electrocardiographic traits 
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have been considered. These currents are summarized in relation to the 
4 phases of the cardiac action potential in Shaw and Rudy’s Figure 1.23
We assumed that most genotypic effects would be through an effect 
on expression level because there are no explanatory protein variants 
in most instances. Using the observed magnitude of genotypic effects 
to estimate likely size of molecular effect, we can read off from the 
model what the percentage change in current should be. Assuming 
a quantitative linear correspondence, this enables induction of the 
predicted magnitude of expression difference according to genotype.
Results
Association analyses were performed on 10 526 participants; 
3443 from the BWHHS, 2024 from GRAPHIC, and 5059 from 
the Whitehall II study. The cohort characteristics are presented 
in Table 1, and the correlations of phenotypes and covari-
ates are presented in online-only Data Supplement Table II. 
The phenotypes were all approximately normally distributed 
(online-only Data Supplement Figure I). Quantile–quantile 
plots with Genomic Inflation Factor for each trait in each 
cohort are presented in online-only Data Supplement Figure II.
Association With Electrocardiographic Traits
In a fixed-effects meta-analysis across 4 phenotypes, 6 inde-
pendent genomic regions were identified containing associ-
ated SNPs at a threshold of P<10−6 (top hits at each locus 
in Table 2, regional association plots in Figure 1, and full 
details of associated SNPs in online-only Data Supplement 
Table IV). In these data, the regression coefficient indicates 
change in phenotype (seconds) per minor allele of an SNP. 
SNPs in the gene for sodium channel, voltage-gated, type V, 
alpha subunit (SCN5A) were associated with both PR inter-
val (top hit rs7372712, P=8.08×10−12) and QRS duration (top 
hit rs7374540, P=5.87×10−9). These 2 SNPs are essentially 
Table 1. Demographic and Clinical Characteristics of the Cohorts
Whitehall II BWHHS GRAPHIC
Males  
(n=3721)
Females  
(n=1338)
Males  
(n=0)
Females  
(n=3443)
Males  
(n=1021)
Females  
(n=1003)
Age, y 60.8 (5.9) 61.2 (6.1) - 68.9 (5.5) 39.4 (15.1) 39.2 (13.9)
BMI, kg/m2 26.6 (3.8) 27.0 (5.5) - 27.8 (4.9) 26.4 (4.3) 25.8 (4.9)
DBP, mm Hg 75.1 (10.4) 73.2 (10.7) - 79.4 (11.9) 73.5 (8.1) 69.9 (6.8)
SBP, mm Hg 128.7 (16.1) 126.5 (18.2) - 147.0 (25.1) 122.5 (10.1) 114.9 (9.8)
% on BP-lowering drugs 23.1 22.1 - 30.0 7.9 5.4
Corrected SBP, mm Hg 132.2 (18.1) 129.7 (20.6) - 151.6 (27.3) 123.4 (10.9) 115.5 (10.6)
PR interval 0.17 (0.02) 0.16 (0.02) - 0.16 (0.02) 0.16 (0.02) 0.15 (0.02)
QRS duration 0.10 (0.01) 0.09 (0.01) - 0.09 (0.01) 0.10 (0.01) 0.09 (0.01)
QT interval (corrected for heart rate) 0.41 (0.02) 0.42 (0.02) - 0.42 (0.02) 0.40 (0.02) 0.41 (0.02)
QRS axis 13.45 (35.00) 22.61 (29.72) - 10.59 (28.87) 36.97 (35.34) 44.13 (29.45)
Table 2. SNPs With the Strongest Evidence of Association at Each Locus Reaching Arraywide Significance in a Meta-Analysis of 
10 526 Individuals
SNP CHR BP
Minor (Coded) 
Allele Gene I2 *
Fixed-Effects  
β (SE)
Fixed-Effects  
P
Random-Effects  
β (SE)
Random-
Effects  
P
PR interval
rs7372712 3 38661196 T SCN5A 0.00 0.00305 (0.00045) 8.08E-12 0.00302 (0.00049) 6.21E-10
rs3807989 7 1.16E+08 A CAV1 67.89 0.00199 (0.00036) 1.99E-08 0.00199 (0.00036) 1.99E-08
QRS duration
rs7374540 3 38609146 C SCN5A 0.00 0.00104 (0.00018) 5.87E-09 0.00104 (0.00018) 5.87E-09
rs3176326 6 36755267 A CDKN1A 0.00 0.00115 (0.00022) 1.41E-07 0.00115 (0.00022) 1.41E-07
rs10988728 9 1.01E+08 G TGFBR1 0.00 0.00352 (0.00079) 7.90E-06 0.00352 (0.00079) 7.90E-06
QTc interval
rs12039600 1 1.6E+08 A NOS1AP 0.00 0.00476 (0.00048) 7.12E-23 0.00476 (0.00048) 7.12E-23
rs12271931 11 2435095 G KCNQ1 36.93 −0.00292 (0.00044) 3.17E-11 −0.00301 (0.00074) 4.36E-05
rs3815459 7 1.5E+08 A KCNH2 0.00 0.00219 (0.00038) 9.44E-09 0.00219 (0.00038) 9.44E-09
rs2267368 22 36895155 A PLA2G6 72.98 −0.00499 (0.00112) 7.80E-06 −0.00499 (0.00112) 7.80E-06
QRS axis
rs2132570 7 45928988 A IGFBP3 0 2.41 (0.51) 2.89E-06 2.41 (0.51) 2.89E-06
rs1934968 10 96731807 A CYP2C9 0 −3.17 (0.68) 3.43E-06 −3.17 (0.68) 3.43E-06
The regression coefficient indicates change in magnitude of phenotype (seconds) per minor allele of an SNP. Minor allele frequencies and missingness are detailed 
in online-only Data Supplement Table III.
*I2 is a measure of heterogeneity in meta-analyses.17
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not in LD (r2=0.02 in HapMap Europeans). PR interval SNP 
rs7372712 is located in an LD block in the 5’ region of SCN5A.
SNP rs3807989 in the CAV1/CAV2 genomic region was also 
associated with PR interval (P=1.99×10−8), with all other signifi-
cant associations in this region attributable to LD with rs3807989. 
In contrast with SNPs in SCN5A, SNPs in the CAV1/CAV2 locus 
did not exhibit any significant association with QRS duration. 
Conversely, in the CDKN1A gene region, SNP rs3176326 dis-
played evidence of association with QRS duration (P=1.41×10−7) 
but little evidence of association with PR interval (P=0.069).
For QTc interval, we observed 56 SNPs in NOS1AP associ-
ated at P<1×10−6, with adjusted analyses (see below) suggest-
ing there may be >1 independent effect.
Nonsynonymous SNP rs1805123 (K899T) in KCNH2 was 
significantly associated with QTc interval (P=8.68×10−7, beta 
coefficient=−0.00174). However, the most significantly asso-
ciated SNP in this region was rs3815459, an intronic SNP 
(P=9.44×10−9, beta coefficient=0.00219).
In KCNQ1, SNP rs12271931 was significantly associated 
with QTc interval (P=3.17×10−11, beta coefficient=−0.00292).
Adjusted Analyses
Analysis adjusted for the lead SNP effect at each locus (Figure 2) 
showed no strong evidence of additional independent SNP 
effects at the CDKN1A locus. For QRS duration, we observed 
Figure 1. Regional association plots 
 illustrating genomic location (x-axis), −log10 
(P value) (y-axis), and linkage disequilibrium 
(r2 on grayscale from white: r2=0–0.2 to black: 
r2=0.8−1) for each of the main associated 
regions. A, SCN5A (PR interval),  
(B) CAV1-CAV2 locus, (C) SCN5A (QRS 
duration), (D) CDKN1A, (E) NOS1AP,  
(F) KCNQ1, (G) KCNH2.
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independent signals for rs6797133 (P=1.42×10−7), rs7624535 
(P=1.02×10−7), rs11710077 (P=6.75×10−4), and rs1805126 
(P=7.59×10−4) adjusted for the top hit rs7374540 in SCN5A. 
For PR interval, we analyzed SNPs in SCN5A adjusted for 
the top hit rs7372712 and observed evidence of independence 
for rs7374540 (P=2.65×10−11), rs12053903 (P=1.52×10−10), 
and rs1805126 (P=2.00×10−7). For QTc interval, the strongest 
independent signal came from rs10918594 (P=4.00×10−8), 
with a number of other SNPs showing evidence of association 
in the analysis adjusted for rs12039600 in NOS1AP. We ana-
lyzed the SNPs in KCNH2 adjusted for our top hit rs3815459 
and observed some evidence of independent effects from 
rs6947240 (P=3.83×10−4) and rs1805123 (P=6.74×10−4).
eQTL Analyses
SNPs with strong evidence of association with electrocardio-
graphic traits in our meta-analysis were investigated for their 
impact on expression of genes in cardiac tissue (Table 3). The 
most associated SNPs for each trait (rs12039600 in NOS1AP for 
QTc interval; rs1934968 in CYP2C9, and rs2132570 in IGFBP3 
for QRS axis; rs7372712 in SCN5A and rs3807989 in CAV1 for 
PR interval) show evidence of association with expression lev-
els (Table 3 and online-only Data Supplement Figure III).
Comparison with Mendelian Conduction Disorders
We compared our results with those reported for single-gene 
arrhythmia disorders and GWAS results, and we present a 
review of rare and common variation influencing electrocardio-
graphic traits in online-only Data Supplement Table I. There 
is no evidence of a role of common variation at the popula-
tion level for a number of genes in which rare mutations have 
reported pathology (within the limitations of HumanCVD cov-
erage). We confirm previously reported findings from a number 
of GWAS for both Mendelian disorder genes (eg, SCN5A) and 
genes for which no Mendelian disorder is known (eg, NOS1AP).
Integrative Modeling
We modeled the effects of changes of ion channel expression 
or activity on electrocardiographic parameters for comparison 
with the observed genotypic effects on these traits. Figure 3 
illustrates the channels and genes considered, with magnitude 
of phenotypic effect shown in milliseconds/allele. In Table 4, 
we show estimates of percentage changes in expression, which 
would be necessary to achieve the percentage changes in each 
specific current consistent with the observed phenotypic effects 
of SNPs in the relevant current-influencing gene. This table is 
based on an explicit assumption that links changes in expres-
sion level to current magnitude (note that for NOS1AP other 
Figure 2. Regional association plots 
adjusted for the most associated single-
nucleotide polymorphisms illustrating 
genomic location (x-axis), −log10 (P value) 
(y-axis), and linkage disequilibrium (r2 on 
grayscale from white: r2=0–0.2 to black: 
r2=0.8–1) for each of the main associated 
regions. (A) SCN5A (PR interval), (B) CAV1-
CAV2 locus, (C) SCN5A (QRS duration), (D) 
CDKN1A, (E) NOS1AP, (F) KCNH2.
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channels may also be influenced by NO).26 Online-only Data 
Supplement Figure IV provides illustrative data on the pre-
dicted effect of INa change on QRS duration. The genotypic 
effects we observe on QRS duration (SCN5A and SCN10A) are 
consistent with an 11% to 12% predicted difference in expres-
sion per allele, whereas for QTc interval the genotypic effects 
are consistent with anywhere from a 1% per allele (KCNE1) to 
a 10% per allele (NOS1AP) difference in expression.
Discussion
Association Analyses
Using the HumanCVD BeadChip we identified 6 regions 
containing SNPs with evidence of association with 
electrocardiographic traits in cohorts representative of 
the general population, broadly consistent with previous 
reports.9,10,27 The high density of SNPs in HumanCVD 
BeadChip for some of these regions offers additional insight 
into possible causal sites or haploblocks around these genes.
SNPs in the gene for the voltage-gated, sodium channel 
type V, alpha subunit (SCN5A) gave highly significant signals 
for both PR interval and QRS duration. The most significant 
SNPs, which were not in LD (r2=0.02 in HapMap Europeans), 
differed for each trait, respectively, rs7372712 and rs7374540 
(online-only Data Supplement Figure V). SNP rs7372712, 
located in an LD block in the 5’ region of SCN5A, appears to 
mark a novel independent effect poorly represented in earlier 
chip-based analyses. Additionally, rs7372712 is essentially 
in linkage equilibrium with the coding SNPs in SCN5A 
claimed to influence electrocardiographic traits, specifically 
rs1805126 (D1819) and rs1805124 (H558R) in Europeans 
(HapMap r2=0.003 and r2=0.011, respectively). In a separate 
gene-focused study, Newton-Cheh et al10 reported SCN5A 
rs11720524, an intron 1 SNP, as the highest ranking marker 
for association of SCN5A genotype with sudden cardiac 
death. There is weak LD (r2=0.112) between rs7372712 and 
rs11720524, and these 2 SNPs colocalize at the 5’ end of 
SCN5A (intron 1, 10.8kb apart). This finding indicates that 
variation in the 5’ region of SCN5A may exert considerable 
influence on both electrocardiographic traits, being our 
leading SNP for PR duration, and clinical outcomes.
SNP rs12053903 in SCN5A was the second most significant 
SNP for PR interval and corresponds with previously reported 
SNP effects.27,28 These SNPs in the 3’ region of SCN5A are in 
1 LD block and may represent the same functional mecha-
nism or (unknown) causal SNP. Our data suggest independent 
effects from variants in the functionally related SCN10A.27,29 
SCN5A SNPs are also reportedly associated with QTc inter-
val; the same SNP and 3’ SCN5A block that we also observed 
to affect PR duration has been associated with QTc interval.10
We replicated a PR interval specific association of 
rs380798927 located in the genomic region of CAV1 and CAV2 
(P=1.99×10−8). All other significant SNP associations in this 
region were explicable by their linkage disequilibrium with 
this SNP. Caveolins act as scaffolds in caveolae, cell membrane 
pits found in almost all myocardial cell types. Receptors, ion 
channels, and endothelial nitric oxide synthase localize at 
caveolae, thus influencing signaling and excitation–contraction 
Table 3. Difference in Gene Expression (Expressed as Difference Per Allele) Among eQTL Genotypes
Left Ventricle Aorta Intima/Media Aorta Adventitia
P Per Allele Effect (95% CI) P Per Allele Effect (95% CI) P Per Allele Effect (95% CI)
NOS1AP rs12039600 0.295 0.98 (0.95–1.02) 0.93 1 (0.96–1.04) 0.0217 1.04 (1.01–1.08)
CYP2C9 rs1934968 0.719 1.01 (0.96–1.06) 0.00117 0.95 (0.91–0.98) 0.555 0.99 (0.95–1.03)
KCNQ1 rs12271931 0.124 0.96 (0.91–1.01) 0.718 1.01 (0.96–1.07) 0.161 0.97 (0.92–1.01)
SCN5A rs7374540 0.137 1.07 (0.98–1.17) 0.371 1.01 (0.98–1.04) 0.478 0.99 (0.96–1.02)
SCN5A rs7372712 0.346 1.06 (0.93–1.21) 0.0129 0.95 (0.91–0.99) 0.513 0.98 (0.94–1.03)
CDKN1A rs3176326 0.116 1.05 (0.99–1.11) 0.846 1.01 (0.96–1.06) 0.847 0.99 (0.94–1.05)
IGFBP3 rs2132570 0.971 1 (0.93–1.07) 0.0423 0.86 (0.75–0.99) 0.00532 0.86 (0.78–0.95)
CAV1 rs3807989 0.00391 0.91 (0.86–0.97) 0.689 0.99 (0.95–1.03) 0.256 0.97 (0.93–1.02)
KCNH2 rs3815459 0.669 1.01 (0.96–1.07) 0.835 1.01 (0.96–1.05) 0.3 0.98 (0.93–1.02)
Values above 1 indicate increased expression with the minor allele of the SNP. Values below 1 indicate decreased expression with the minor allele of the SNP. SNPs 
from Table 2 were tested against the closest gene. FDR 5% corresponds to P≤0.00532 in this set of tests. CI indicates confidence interval.
Figure 3. Schematic of the modeling approach used. Variants in 
labeled genes are assumed to influence the channel indicated. 
The schematic is partitioned into channels affecting QRS dura-
tion, and channels affecting QTc interval. The per-allele effect of 
the most significant allele in each gene on either QRS or QTc is 
indicated in milliseconds.
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coupling. Altered caveolin activity alters NO modulation of 
membrane excitability.30 This genetic effect, as for NOS1AP 
on QTc interval (see below), may therefore involve NO, but 
equally plausibly could involve ryanodine receptors and 
calcium or sodium channels.31 A systems view of the NO 
system is presented in the online-only Data Supplement.
SNPs in CDKN1A were uniquely associated with QRS dura-
tion consistent with previous reports.24,32 It is likely that our lead 
SNP marks the same effect as previously reported. CDKN1A 
encodes cyclin-dependent kinase inhibitor 1A, which is 
involved in cell cycle regulation.33 The mechanism by which a 
cell cycle gene could differentially influence QRS duration rela-
tive to other electrocardiographic traits remains obscure but may 
reflect an influence on ventricular development or remodeling, 
given that the QRS complex represents ventricular depolariza-
tion. Alternatively, it could influence ventricular depolarization 
through an effect on peripheral circulatory resistance.
Numerous studies have reported association of common 
variation in NOS1AP with QTc interval, and our results are in 
broad accord with data that suggest 3 independent effects.10 
Other SNPs in our data and reported in the literature do not 
appear to be independent of these. NOS1AP encodes carboxyl-
terminal PDZ ligand of neuronal nitric oxide synthase pro-
tein, a protein that binds neuronal NO synthase (NOS1) via a 
C-terminal binding domain and other proteins such as Dexras1 
and synapsins via an N-terminal phosphotyrosine-binding 
domain. In the heart and ventricular myocytes, carboxyl-ter-
minal PDZ ligand of neuronal nitric oxide synthase protein 
interacts with NOS1 to accelerate cardiac repolarization by 
inhibition of L-type calcium channels, which generate a slow 
depolarizing current.26 NOS1AP association plots for all 4 traits 
are presented in online-only Data Supplement Figure VI.
At the KCNH2 locus, we replicated findings for a nonsynon-
ymous SNP, rs1805123 (K899T) widely reported for associa-
tion with QTc and with electrophysiological effects in vitro.34–38 
We also replicated findings for SNPs emergent from published 
GWAS,9,10,24,29 where our best proxy was rs6972137 (r2=0.083 
with rs1805123 in HapMap Europeans). Our lead SNP effect, 
rs3815459 (intronic), is inconsistent with rs1805123 being 
the only functional site in KCNH2. Our data support reports 
of independent effects in KCNH2.10 We note that 1 overarch-
ing LD block spans both KCNH2 and NOS3 (online-only Data 
Supplement Figure VI), separated by ≈10 kb, and speculate 
that intronic or intergenic SNPs ascribed to KCNH2 could 
alternatively mark effects of NOS3 (also a plausible candidate 
for effects on QTc, particularly considering the recent discov-
ery of unexpected NOS1AP association with QTc).10
Our results also broadly replicate earlier observations 
for KCNQ1.9,24 Numerous reports have implicated KCNQ1 
variation in type 2 diabetes mellitus risk39–42 and also in 
association with adrenaline, adenosine diphosphate,43 
and alpha2-macroglobulin levels.44 The diabetes mellitus 
SNP is not represented in our data; however rs179429, 
reportedly43 associated with adrenaline levels, is present 
but showed no association with QTc. It seems unlikely 
that KCNQ1 effects on QTc could be explained by indirect 
effects through adrenaline level rather than by direct effects 
on cardiac outward potassium current.
Integrative Modeling
It is notable that common variants are observed affecting 5 of the 
8 or so ionic currents (Figure 3). We observe a strong correspon-
dence between the leading genotypic effects on PR, QRS, and 
QTc intervals and the major genes encoding products influencing 
those traits (eg, INa: SCN5A on PR and QRS duration, IKr: KCNH2 
on QTc, and IKs: KCNQ1 on QTc). CACNA1C was represented by 
193 SNPs in the HumanCVD array, but none showed any evidence 
of association (all P>0.05). However, NOS1AP, which influences 
ICa(L), showed strong evidence of association with QTc interval. 
From a modeling perspective (online-only Data Supplement 
Figure IV), percentage changes in QRS duration are an order of 
magnitude greater per percent change in INa (eg, through possible 
differential level of expression according to genotype). In Table 
4 it is evident that remarkably small (down to 1%) effects can 
be detected for QTc interval compared with PR and QRS dura-
tion, possibly reflecting the relatively smaller SD of QTc. There 
is no evidence of effect on QTc for SCN5A SNPs with prominent 
effects on QRS and PR duration. From the predicted QRS dura-
tion based on percentage change in INa, the observed ≈1 ms/allele 
effect of SCN5A rs7374540 on QRS duration would correspond 
with 12% change in INa, possibly represented as a 12% difference 
of SCN5A allelic expression were INa to directly correlate with 
SCN5A expression. Such a difference would be predicted to exert 
a small effect on QTc, creating a 0.3% difference per allele. Mean 
QTc was ≈0.42 seconds, which predicts a beta of ≈0.001; how-
ever, we did not observe this finding in our association results.
Generally, the various potassium and calcium channel cur-
rents have little impact on QRS duration, thus the genotypes 
Table 4. Estimates of Percentage Changes in Expression Predicted to be Necessary to Achieve the Model Predicted Change in Each 
Specific Current
ECG Feature Gene Current Observed Effect (ms/allele) Predicted % Difference of Expression Per Allele
QRS SCN5A INa 1 12
QRS SCN10A INa 0.5 11
QTc NOS1AP ICa(L)* 4.8 10
QTc KCNH2 IKr 2.3 5
QTc KCNQ1 IKs 3.1 3
QTc KCNE1 IKs 1.0 1
QTc KCNJ IK1 1 2.5
Observed effect was used in electrophysiological models of QRS and QTc (see Methods) to estimate % change of current which would generate that effect. It was 
then assumed that % change of current would directly correspond with % change of gene expression.
*This appears to be the primary mode of action of NOS1AP,26 but other channels may also be influenced by NO.26
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influencing QTc are unlikely to show detectable effects on 
QRS duration. We also cannot readily integrate CAV1/2 or 
CDKN1A to this model except to note CAV1/2 interaction with 
channels, receptors, and NO signaling. Finally, our assumption 
of a quantitative linear correspondence between expression and 
phenotypic effect is a potential limitation of the approach.
eQTL Analyses
We tested the top associated SNPs for each gene (Table 2) for 
differential expression by genotype. rs12039600 in NOS1AP, 
rs7372712 in SCN5A, rs2132570 in IGFBP3, rs1934968 in 
CYP2C9, and rs3807989 in CAV1 all showed evidence of 
eQTL effects (Table 3), with per-allele effects of 4%, 5%, 
14%, 5%, and 9%, respectively. Because the SNP associations 
with electrocardiographic traits do not appear to reflect cod-
ing variants, the ECG effects may operate through expression 
levels. Our findings support this hypothesis for these SNPs. 
rs12039600 is in intron 1 of NOS1AP, and rs7372712 is in the 
5’ region of SCN5A. These may therefore mark a haplotypic 
effect on allelic expression in the promoter regions of these 
genes. In our eQTL analyses for NOS1AP rs12039600, a 4% 
difference of allelic expression was observed. The G allele 
leads to lower expression, which would imply less inhibition 
of the depolarizing L-type calcium channel, leading to a lon-
ger QTc interval. This finding is consistent with the observed 
G allele association with QTc. The IGFBP3, CYP2C9, and 
CAV1 eQTL effects were greater than might be anticipated 
from their regression coefficients (eg, 9% effect per allele on 
expression vs. 1% per allele for rs3807989 on PR interval); 
however, their mechanisms of effect are complex and cannot 
readily be modeled. It should be noted that we did not find 
complete consistency of allelic imbalance by SNP across dif-
ferent vascular tissues. Also, eQTL analysis for the ideal tis-
sue (eg, ventricular myocardium for QRS) was not available.
Conclusions
We have replicated across the range of electrocardiographic traits 
a number of previously reported SNPs. Our data point to a previ-
ously unrecognized allele and region effect in SCN5A on PR and 
QRS durations and confirm multiple allelic effects of NOS1AP 
on QTc. We also identify relevant eQTL effects in NOS1AP, 
SCN5A, CYP2C9, IGFBP3, and CAV1. We consider the genetic 
findings in the light of both biological knowledge and a general 
systems model of electrocardiographic traits, representing a first 
step toward an integrative genetic model of the ECG as a com-
plex trait. The impact of specific allelic differences in this model 
may be of value in predicting the effects of drugs targeting spe-
cific gene products influencing electrocardiographic traits.
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CLINICAL PERSPECTIVE
Electrocardiographic traits are substantially heritable determinants of risk of arrhythmias and sudden cardiac death. We 
describe a genetic association analysis of PR interval, QRS axis, QRS duration, and QTc interval in 3 population cohorts. 
Genotyping was performed using the HumanCVD high-density array, and electrocardiographic traits were derived from 
digital electrocardiographic data using the Glasgow ECG analysis program. Our analyses confirmed a number of previously 
reported genetic associations and identified a novel independent genetic locus near the voltage-gated sodium channel gene 
SCN5A. Genetic associations were followed up by analysis of the effects of these loci on gene expression in heart tissue 
and by modeling the expected effects on electrocardiographic parameters using an established model of electrical action 
potentials of human ventricular cells. These analyses offered additional insight into the molecular mechanisms underlying 
variability in electrocardiographic traits. The findings contribute toward the development of an integrated description of the 
molecular system and common human variation underpinning electrocardiographic pathophysiology.
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Supplementary Materials and Methods 
Study Cohorts 
British Women’s Heart and Health Study (BWHHS): The BWHHS is a prospective cohort study of British women  aged 60 to 79 years at baseline 
assessment (1999-2001). The study comprises 4286 women randomly selected from 23 British towns. Baseline measurements are described in 1 and follow-
ups in 2. Illumina HumanCVD genotype data are available on 3443 women (European-British ancestry) from the cohort. ECG measurements were carried out 
in the baseline assessment. Informed consent was obtained from all participants and the study was approved by UK NHS local and multicentre ethics 
committees. 
Genetic Regulation of Arterial Pressure of Humans in the Community (GRAPHIC) Study: The GRAPHIC Study comprises 2024 individuals from 520 nuclear 
families of White-European origin recruited from the general population for the purpose of investigating the genetic determinants of blood pressure and 
related cardiovascular traits. Families were recruited through participating family practitioners in Leicestershire, UK, between 2003 and 2005 and included if 
both parents aged 40-60 years and two offspring 18 years wished to participate. There was no preferential selection based on history of hypertension, but 
subjects were excluded if they had known renal disease. A detailed medical history was obtained from study subjects by standardized questionnaires and 
clinical examination was performed by research nurses following standard operating procedures. Measurements included height, weight, waist-hip ratio, 
clinic and ambulatory blood pressure and 12-lead ECGs. Blood samples were obtained for laboratory analysis. Analysis used generalized estimating 
equations (GEE). We have shown (in-house) that the results from a GEE in GRAPHIC are broadly similar to the results we obtain from Merlin 
(http://www.sph.umich.edu/csg/abecasis/Merlin/index.html) giving us confidence in their ability to adequately adjust for the familial correlation. The study 
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was approved by the Leicestershire Research Ethics Committee, and all subjects provided written informed consent. The study conforms to the principles 
outlined in the Declaration of Helsinki, and all procedures followed were in accordance with institutional guidelines. Further details are provided 
elsewhere3. 
Whitehall II Study: The Whitehall II study recruited 10,308 participants (70% men) between 1985 and 1989 from 20 London-based Civil service departments. 
Clinical measurements are taken every 5 years. Blood samples for DNA were collected in phase 7 (2002–2004) from over 6000 white-European participants. 
ECG measurements and other phenotype information from phase 7 were used in this study since this phase had the largest number of ECG measurements. 
Informed consent was obtained from all participants and the study was approved by UK NHS local ethics committees. 
 
The Nitric Oxide system 
The NO system is widely represented in the heart and vasculature, with NOS1 (neuronal NOS) expressed in conduction tissue, intracardiac neurons and 
sarcoplasmic reticulum of myocytes; NOS3 (endothelial NOS) expressed in coronary endothelium, endocardium and sarcolemma and T-tubules of myocytes; 
and NOS2 (inducible NOS) induced by inflammatory cytokines. In the peripheral vascular system, vascular smooth muscle relaxation through NO action via 
cGMP can alter cardiac workload and hence ECG. By direct action in the heart, much influence is on the calcium signalling components of the ECG, with 
NOS1 localised near ryanodine receptors and Ca2+ ATPase (SERCA2a) in the sarcoplasmic reticulum, and NOS3 localised in sarcolemmal caveolae with 
receptors and L-type calcium channels4.  NOS1, 2 and 3 genes were respectively represented by 117, 48 and 23 SNPs in the HumanCVD array but no 
variation reached chip-wide significance for any conduction trait. Our high density of coverage, and the fact that these genes have not emerged in GWAS of 
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any disease, suggests that there may not be much functionally meaningful common variation in these important genes, in contrast with NOS1AP. However, 
for NOS3, we cannot rule out the possibility that effects apparently from the directly adjacent KCNH2 gene, might actually represent SNPs influencing gene 
regulation of NOS3. NOS1AP and NOS1 also interact with the second PDZ domain of DLG4 (discs large homolog 4 or post-synaptic density protein 95), 
respectively through their C terminus and PDZ domain; DLG4 is a member of the membrane-associated guanylate kinase family and with DLG2 is recruited 
into neuronal potassium channel clusters.  DLG4, 3 and 2 are represented in the HumanCVD array.  In DLG4, an intronic SNP  showed weak evidence of 
association with QTc duration (p = 0.018) but numerous SNPs in DLG3 (on the X chromosome) showed p values in the range 0.001-0.0001.  While this does 
not reach our pre-defined significance threshold, it suggests that there might be variation in additional functional products centred around NOS1AP 
influencing cardiac repolarization that could be identified with large collections. 
Supplementary Tables 
 
Supplementary Table 1:  Reported Mendelian and common genetic variants related to cardiac conduction traits.  
Gene Single gene arrhythmia disorder known (based on data in OMIM extracted 
May 2011 
5
) 
 
Mechanism Complex 
trait ECG 
effect 
observed 
SNP 
coverage 
in our 
data 
Reported SNPs 
in other studies 
Most significant 
SNP in our study 
and r
2
 with other 
reported SNPs 
 
ABCC9 Yes 
3-BP DEL, 4-BP INS, EX38 and ALA1513THR (rs121909304) with dilated 
cardiomyopathy
6
 
Sulfonylurea 
receptor; 
sulfonylureas inhibit 
activite of KATP 
channels. 
No 25 None rs4148674: 
p=0.015266994 with 
T axis 
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AKAP9 Yes 
SER1570LEU (rs121908566) with long QT
7
 
Part of the IKs PKA 
complex  binding 
KCNQ1 C terminus 
and PKA. Likely 
regulatory function. 
No 5 None rs6960867: 
p=0.008763673 with 
QRS duration 
rs6960867: 
p=0.039303174 with 
QTc interval 
 
ANK2 Yes 
GLU1425GLY (rs72544141) with cardiac arrhythmia
8
 
THR1626ASN, LEU1622ILE (rs35530544), GLU1813LYS (rs45454496) with 
cardiac arrhythmia
9
  
ARG1788TRP with long QT
9
 
Involved in 
distribution of ion 
channels  
No 3 None rs28377576: 
p=0.088422556 with 
QTc interval 
 
CACNA1C Yes 
GLY406ARG (rs79891110) with Timothy Syndrome
10
 
GLY402SER (rs80315385) with Timothy Syndrome
11
 
GLY490ARG and ALA39VAL with Brugada Syndrome
12
 
Calcium channel 
mediating calcium 
ion influx 
No 194 None rs11832738: 
p=0.00067468 
with QRS axis 
 
CAV3 Yes 
21 reported mutations in OMIM causing long QT, cardiomyopathy, rippling 
muscle disease, limb-girdle muscular dystrophy 
Long QT mutations: 
SER141ARG (rs104893713), PHE97CYS (rs104893714), THR78MET 
(rs72546668), ALA85THR (rs104893715) with long QT
13
 
Muscle-specific 
caveolin, a scaffold 
protein in caveolae. 
No 10 None rs237872: 
p=0.060216592 
with QTc interval 
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VAL14LEU (rs121909281), LEU79ARG (rs121909282) with long QT
14
 
CASQ2 Yes 
ASP307HIS with ventricular tachycardia
15
 
16-BP DEL, NT339, LEU167HIS with ventricular tachycardia
16
 
Main calcium ion 
reservoir in the 
cardiac myocyte 
sarcoplasmic 
reticulum 
Yes 14 rs4074536 with 
QRS duration 
(p=2.36x10
-8
)
17
 
rs10754355: 
p=0.030020001 
with T axis 
(Hapmap CEU r2 = 
0.015 with 
rs4074536). 
rs4074536: 
p=0.279696876 
with QRS duration 
 
DMPK 
3'UTR 
Yes 
(CTG)n EXPANSION with myotonic dystrophy
18
 
A protein kinase 
with a functional 
role in myotonic 
dystrophy.  
No 3 None rs16939: 
p=0.034070514 
with PR interval 
 
GJA5 Yes 
ALA96SER (rs121434557), PRO88SER (rs121434558) with atrial fibrillaion
19
 
A connexin protein 
with a structural 
role in gap junctions 
between cardiac 
myocytes. 
No 9 None rs6703824: 
p=0.004763167 
with QTc interval 
 
GPD1L Yes 
ALA280VAL (rs72552291) with Brugada syndrome
20
 
GLU83LYS (rs72552292), ILE124VAL (rs72552293), ARG273CYS (rs72552294) 
with Brugada syndrome
21
 
A gene involved in 
Brugada syndrome, 
possibly influencing 
sodium transport. 
No 0 None N/A  
HCN4 Yes A nucleotide-gated 
ion channel with a 
No 14 None rs11635910: 
p=0.003807708 
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SER672ARG (rs104894488) with sick sinus syndrome
22
 
1-BP DEL, 1631C with sick sinus syndrome
23
 
ASP553ASN (rs104894485) with sick sinus syndrome
24
 
GLY480ARG (rs121908411) with sick sinus syndrome
25
 
4-BP INS, GTGA with Brudgada syndrome
26
 
role in cardiac 
pacemaking 
with QRS duration 
KCNA5 Yes 
GLU375TER (rs121908590) with familial atrial fibrillation
27
 
THR527MET (rs121908591), ALA576VAL (rs121908592), GLU610LYS 
(rs121908593) with familial atrial fibrillation
28
 
Voltage-gated 
potassium channel 
expressed in heart. 
No 7 None rs9788217: 
p=0.126869271 
with T axis 
 
KCNE1 Yes 
THR59PRO AND LEU60PRO with Jerfell and Lange-Nielsen syndrome
29
 
THR7ILE (rs28933384), ASP76ASN (rs74315445) with Jerfell and Lange-Nielsen 
syndrome
30
 
ASP76ASN (rs74315445), SER74LEU (rs74315446) with long QT
31
 
ASP85ASN (rs1805128) with long QT
32
 
Voltage-gated 
potassium channel 
expressed in heart. 
No 24 None rs1012945: 
p=0.034395743 
with QTc interval 
 
KCNE2 Yes 
GLN9GLU (rs16991652), MET54THR (rs74315447), ILE57THR (rs74315448) with 
long QT
33
 
ARG27CYS (rs74315449) with long QT
34
 
Voltage-gated 
potassium channel. 
No 5 None rs12626687: 
p=0.06693889 
with T axis 
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PHE60LEU (rs16991654) with long QT
35
 
KCNH2 Yes 
22 long QT and 1 short QT mutations reported in OMIM: 
ALA561VAL; ASN470ASP; IVS3, G-C, +1; ILE593ARG (rs28928904); VAL822MET; 
27-BP DEL; 1-BP DEL; GLY628SER; ARG582CYS; GLY572ARG (rs9333649); 
ALA490THR (rs28928905); TRP1001TER; SER818LEU; ARG784TRP 
(rs12720441); THR65PRO; ARG752GLN; IVS10, G-A, +1; 1-BP INS, 2775G; 
ASN861ILE; ARG948CYS; ARG100GLY; ARG913VAL (rs77331749); ALA558PRO 
with long QT (http://www.ncbi.nlm.nih.gov/omim/152427?report=Variants) 
ASN588LYS (rs104894021) with short QT 
(http://www.ncbi.nlm.nih.gov/omim/152427?report=Variants) 
Voltage-gated 
potassium channel 
(HERG). 
Yes 9 rs2968863 with 
QT interval 
(p=3.79x10
-8
)
36
 
rs2968864 with 
QT interval 
(p=8x10
-16
) and 
rs4725982 with 
QT interval 
(p=5x10
-16
)
37
 
rs3815459: 
p=9.44x10-9 with 
QTc interval 
 
KCNJ2 Yes 
12 mutations reported with Andersen Cardiodysrhythmic Periodic Paralysis 
and 1 mutation with short QT in OMIM: 
ASP71VAL (rs104894575); ARG218TRP (rs104894578); GLY300VAL 
(rs104894579); 12-BP DEL, NT513; 6-BP DEL, NT1167; ARG67TRP 
(rs104894580); PRO186LEU (rs104894581); VAL302MET (rs104894582); 
ASN216HIS (rs104894583); THR75ARG (rs104894585); CYS54PHE; THR305PRO 
with Andersen Cardiodysrhythmic Periodic Paralysis 
(http://www.ncbi.nlm.nih.gov/omim/600681?report=Variants) 
 ASP172ASN (rs104894584) with short QT 
(http://www.ncbi.nlm.nih.gov/omim/600681?report=Variants) 
Inwardly rectifying 
potassium channel 
expressed in heart. 
Yes 3 rs17779747 with 
QT interval 
(p=6x10
-12
)
36
 
 
rs1468472: 
p=0.169625286 
with QTc interval 
 
KCNQ1 Yes 
30 long QT, 1 short QT and 8 other mutations reported in OMIM: 
Voltage-gated 
potassium channel 
Yes 180 rs12296050 with 
QT interval 
rs12576156: 
p=0.0000108 with 
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SER140GLY (rs120074192) with atrial fibrillation 
(http://www.ncbi.nlm.nih.gov/omim/607542?report=Variants) 
7-BP DEL/8-BP INS, N; 1-BP INS, 282G; TRP305SER (rs120074186); 2-BP DEL; 
20-BP DEL, NT1892; THR587MET (rs120074189); IVS1 with Jervell and Lange-
Nielsen syndrome 1 
(http://www.ncbi.nlm.nih.gov/omim/607542?report=Variants) 
3-BP DEL; ALA178PRO (rs120074177); GLY189ARG (rs104894252,104894255); 
ARG190GLN (rs120074178); VAL254MET (rs120074179); LEU273PHE 
(rs120074180); GLY306ARG (rs120074181); THR312ILE (rs120074182); 
ALA341GLU (rs12720459); ALA341VAL (rs12720459); GLY345GLU 
(rs120074183); GLY314SER (rs120074184); ARG555CYS (rs120074185); 
ALA300THR (rs120074187); 3-BP DEL, PHE339DEL; 9-BP DEL, NT373; IVS5, -1; 
CODON 344 SPLICE MUT; 1-BP INS; GLY589ASP (rs120074190); PRO117LEU 
(rs120074191); ARG583CYS (rs17221854); GLY269SER (rs120074193); 
GLY269ASP (rs120074194); VAL254MET AND VAL417; 1-BP DEL/2-BP INS, N; 
ARG518TER (rs17215500); ALA525THR (rs120074188); 1-BP DEL, 562T; 
ARG243PRO (rs120074196) with long QT 
(http://www.ncbi.nlm.nih.gov/omim/607542?report=Variants) 
VAL307LEU (rs120074195) with short QT 
(http://www.ncbi.nlm.nih.gov/omim/607542?report=Variants) 
expressed in heart. (p=3x10
-17
)
36
 
rs12576239 with 
QT interval 
(p=1x10
-15
) and 
rs2074238 with 
QT interval 
(p=3x10
-17
)
37
 
QTc interval 
LMNA Yes 
52 variants reported in OMIM, 11 with dilated cardiomyopathy and 41 with 
other conditions (including muscular dystrophy, charcot-marie-tooth disease, 
lipdystrophy and others): 
ARG60GLY (rs28928900); LEU85ARG (rs28933090); ASN195LYS (rs28933091); 
GLU203GLY (rs28933092); ARG571SER (rs80338938); 1-BP DEL, 959T; 
GLU161LYS (rs28933093); 1-BP INS, 28A; SER573LEU (rs60890628); ALA57PRO 
Gene encodes 
lamins, structural 
proteins responsible 
for nuclear 
shape/size. 
No 7 None rs2485662: 
p=0.0000128 with 
QRS axis 
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(rs28928903); LEU59ARG with dilated cardiomyopathy  
ARG298CYS (rs59885338); HIS222TYR (rs28928901); GLN6TER (rs61046466); 
ARG453TRP (rs58932704); ARG527PRO (rs57520892); LEU530PRO 
(rs60934003); ARG133PRO (rs60864230); GLU358LYS (rs60458016); IVS9AS, T-
G, -12; GLY608GLY (rs58596362); GLY608SER (rs61064130); VAL607VAL 
(rs59886214); GLU145LYS (rs60310264); LEU140ARG (rs60652225); 
ARG482GLN (rs11575937); ARG482TRP (rs57920071); ARG482LEU 
(rs11575937); GLY465ASP (rs61282106); ARG582HIS (rs57830985); 
ARG133LEU (rs60864230); IVS8, G-C, +5; ASP230ASN (rs61214927); 
ARG399CYS (rs58672172); ARG527HIS (rs57520892); ARG527CYS 
(rs57318642); LYS542ASN (rs56673169); ALA529VAL (rs60580541); 
ALA529THR; ARG471CYS (rs28928902); VAL440MET; SER143PHE (rs58912633); 
LEU380SER; ARG249TRP; 3-BP DEL, 94AAG; ARG377HIS (rs61672878); 3-BP 
DEL, EXON 3; IVS9, G-C, +5; TYR259TER (rs58048078); GLN493TER 
(rs56699480); IVS11, G-A, +1; ARG644CYS with other conditions 
PLN Yes 
ARG9CYS (rs111033559) with dilated cardiomyopathy
38
 
LEU39TER (rs111033560) with dilated cardiomyopathy
39
 
3-BP DEL, 39AGA with dilated cardiomyopathy
40
 
Phospholamban, a 
substrate for cAMP-
dependent protein 
kinase in heart. 
Yes 3 rs11970286 with 
QT interval 
(p=2x10
-24
) and 
rs12210810 with 
QT interval 
(p=2x10
-17
)
36
 
rs11153730 with 
QT interval 
(p=2x10
-29
)
41
 
rs11756438 with 
QT interval 
(p=5x10
-22
)
37
 
rs11153730 with 
rs3752581: 
p=0.00143318 
with QTc interval 
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QRS duration 
(p=1x10
-18
)
17
 
PRKAG2 Yes 
11 mutations reported in OMIM, 2 with Wolff-Parkinson-White syndrome, 8 
with familial hypertrophic cardiomyopathy and 1 with glycogen storage 
disease of the heart: 
HIS142ARG (rs121908988); 3-BP INS, 327TTA; THR400ASN (rs28938173); 
ASN488ILE (rs121908989); TYR487HIS; HIS530ARG; GLU506GLN; SER548PRO 
with familial hypertrophic cardiomyopathy 
(http://www.ncbi.nlm.nih.gov/omim/602743?report=Variants) 
ARG302GLN (rs121908987); ARG531GLY (rs121908990) with Wolff-Parkinson-
White syndrome 
(http://www.ncbi.nlm.nih.gov/omim/602743?report=Variants) 
ARG531GLN (rs121908991) with glycogen storage disease of the heart 
(http://www.ncbi.nlm.nih.gov/omim/602743?report=Variants) 
A protein kinase 
with a role in 
metabolic stress-
sensing. 
No 113 None rs1860744: 
p=0.001899017 
with QRS duration 
 
RYR2 Yes 
10 mutations listed in OMIM, 8 with catecholaminergic polymorphic 
ventricular tachycardia, 2 with familial arrhythmogenic right ventricular 
dysplasia: 
SER2246LEU (rs121918597); ARG2474SER (rs121918598); ASN4104LYS 
(rs121918599); ARG4497CYS (rs121918600); PRO2328SER (rs121918603); 
VAL4653PHE (rs121918604); GLN4201ARG (rs121918605); ALA4860GLY 
(rs121918606) with catecholaminergic polymorphic ventricular tachycardia 
ASN2386ILE (rs121918601); LEU433PRO (rs121918602) with familial 
Cardiac ryanodine 
receptor (calcium-
release channel). 
No 194 None rs2152885: 
p=0.005047473 
with QRS axis 
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arrhythmogenic right ventricular dysplasia 
SCN1B Yes 
CYS121TRP (rs104894718) with generalized epilepsy
42
 
IVS2AS, A-C, -2 with generalized epilepsy
43
 
536G-A, TRP179TER with Brugada syndrome
44
 
GLU87GLN (rs121434627), 537G-A, TRP179TER with nonspecific cardiac 
conduction defect
44
 
Voltage-gated 
sodium channel 
expressed in heart. 
No 0 None N/A  
SCN4B Yes 
LEU179PHE (rs121434386) with long QT
45
 
Voltage-gated 
sodium channel. 
No 0 None N/A  
SCN5A Yes 
41 mutations listed in OMIM, with a range of conduction-related phenotypes: 
VAL232ILE and LEU130 (rs41313031,45471994); ARG1232TRP AND THR16; 
IVS7DS, 2-BP INS; 1-BP DEL, VAL1398TER; ARG1512TRP; ALA1924THR; 
ARG367HIS (rs28937318); ALA735VAL; ARG1193GLN (rs41261344); 
TYR1795HIS; GLY1262SER; GLU1053LYS; TRP1421TER with Brugada Syndrome 
GLY514CYS with Nonprogressive Cardiac Conduction Defect  
ASP1275ASN; THR220ILE (rs45620037); 2-BP INS, NT2550; ASP1595HIS with 
Dilated Cardiomyopathy 
1-BP DEL, 5280G with Nonprogressive Heart Block  
ASP1819ASN; LYS1505/PRO1506/GLN1; ARG1644HIS (rs28937316); 
ASN1325SER (rs28937317); ARG1623GLN; GLU1784LYS; 3-BP INS, 5537TGA; 
Cardiac voltage-
gated sodium 
channel. 
Yes 40 rs11129795 with 
QT interval 
(p=5x10
-14
)
36
 
rs12053903 with 
QT interval 
(p=1x10
-14
)
37
 
rs11708996 with 
PR interval 
(p=6x10
-26
)
46
 
rs3922844 with 
PR interval 
(p=3x10
-23
)
47
 
rs7372712: 
p=6.21x10-10 with 
PR interval 
rs7374540: 
p=5.87x10-9 with 
QRS duration 
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SER941ASN; ALA997SER; ARG1826HIS; TYR1795CYS; SER1103TYR (rs7626962) 
with long QT 
IVS22DS, T-C, +2; ASP1595ASN; GLN298SER; THR512ILE AND HIS558 
(rs1805124) with Progressive Familial Heart Block 
PRO1298LEU; GLY1408ARG; THR220ILE (rs45620037); ARG1623TER with Sick 
Sinus Syndrome  
SER1710LEU with Paroxysmal Familial Ventricular Fibrillation 
Genes associated with ECG phenotypes from genome-wide association studies (GWAS)   
ARHGAP24 No Negative regulator 
of Rho GTPases. 
Yes 0 rs7692808 with 
PR interval 
(p=6x10
-20
)
46
 
N/A  
CAV1-
CAV2 
No Caveolins, scaffold 
proteins in 
caveolae. 
Yes 16 rs3807989 with 
PR interval at 
(p=4x10
-28
)
46
 
rs4730743: 
0.00000443 with 
PR interval 
 
CDKN1A No Role in cell cycle 
arrest following 
DNA damage. 
Yes 18 rs9470361 with 
QRS duration 
(p=3x10
-27
)
17
 
rs1321311 with 
QRS duration 
(p=2.7x10
-10
)
48
 
rs3176326: 
0.000000141 with 
QRS duration 
 
DKK1 No Inhibitor of WNT 
signalling. 
Yes 0 rs1733724 with 
QRS duration 
(p=3x10
-8
)
17
 
N/A  
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MEIS1 No Homeobox gene 
implicated in 
leukemia. 
Yes 38 rs11897119 with 
PR interval 
(p=5x10
-11
)
46
 
rs12619205: 
0.00042975 with 
PR interval 
 
MYH6 Yes 
7 mutations listed in OMIM, 5 cardiomyopathy, 1 atrial septal defect and 1 
hybrid gene resulting in a heavy chain variant: 
ILE820ASN with Atrial Septal Defect 
(http://www.ncbi.nlm.nih.gov/omim/160710?report=Variants) 
PRO830LEU; ALA1004SER; GLU1457LYS; ARG795GLN; GLN1065HIS with 
Familial Hypertrophic Cardiomyopathy 
(http://www.ncbi.nlm.nih.gov/omim/160710?report=Variants) 
MYH6/MYH7 HYBRID with Heavy Chain Variant of Cardiac Myosin, Cardiac 
(http://www.ncbi.nlm.nih.gov/omim/160710?report=Variants) 
Cardiac myosin, 
with mutations 
causing 
cardiomyopathy. 
Yes 1 rs365990 with 
resting heart 
rate (p=4x10
-14
)
49
 
rs365990: 
0.050143516 with 
QRS duration 
 
NKX2-5 Yes 
17 mutations listed in OMIM, 9 atrial septal defect, 2 atrioventricular block, 4 
Tetralogy of Fallot and 2 hypothyroidism: 
THR178MET (rs104893900); GLN170TER (rs104893901); GLN198TER 
(rs104893903); 7-BP DEL; 2-BP DEL, 223CG; 1-BP DEL, 262G; ARG190CYS 
(rs104893906); TYR256TER (rs104893907); ASP299GLY with Atrial Septal 
Defect With Atrioventricular Conduction Defects 
IVS1DS, G-T, +1 with Idiopathic Atrioventricular Block 
LYS183GLU with Somatic Atrioventricular Septal Defect 
ALA119SER; ARG161PRO with Congenital Hypothyroidism 
Homolog of a 
mouse homebox 
gene assumed to be 
important in cardiac 
differentiation 
Yes 1 rs251253 with 
PR interval 
(p=9x10
-13
)
46
 
rs703752: 
0.014571864 with 
QRS duration 
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ARG25CYS (rs28936670); GLU21GLN (rs104893904); ARG216CYS 
(rs104893905); ALA219VAL (rs104893902) with Tetralogy Of Fallot 
NOS1AP No Protein that binds 
the signalling 
molecule neuronal 
nitric oxide 
synthase. 
Yes 159 rs10494366 with 
QT interval 
(p=1x10
-10
)
50
 
rs12143842 with 
QT interval 
(p=2x10
-78
) and 
rs4657178 with 
QT interval 
(p=7x10
-33
)
36
 
rs12029454 with 
QT interval 
(p=3x10
-45
), 
rs16857031 with 
QT interval 
(p=1x10
-34
) and 
rs12143842 with 
QT interval 
(2x10
-78
)
37
 
rs2880058 with 
QT interval 
(2x10
-10
)
51
 
rs12039600: 
7.12x10-23 with 
QTc interval 
 
SCN10A No Voltage-gated 
sodium channel not 
expresed in heart. 
Yes 1 rs6800541 with 
PR interval 
(p=2x10
-74
)
46
 
rs6800541 with 
rs7373934: 
0.071627558 with 
QTc interval 
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PR interval 
(p=9.7x10
-17
)
52
 
SOX5 No Related to SRY. Yes 5 rs11047543 with 
PR interval 
(p=3x10
-13
)
46
 
rs4147498: 
0.006349122 with 
QRS duration 
 
TBX5-TBX3   Yes 21  rs1946293: 
0.000556618 with 
PR interval 
 
WNT11   Yes 0  N/A  
 
 at GLASGOW UNIV LIB on February 19, 2013circgenetics.ahajournals.orgDownloaded from 
Gaunt et al Supplementary Information        p.17/34 
Supplementary Table 2: Trait and Covariate Correlations 
   PR Interval QRS Axis QRS Duration QTc Interval 
 
BWHHS PR Interval 1.000 
 
   
GRAPHIC     
WHI II     
BWHHS QRS Axis -0.121 1.000   
GRAPHIC  -0.184    
WHII  -0.148    
BWHHS QRS Duration 0.061 -0.140 1.000  
GRAPHIC  0.041 -0.123   
WHII  0.066 -0.201   
BWHHS QTc Interval (QT 
corrected for heart 
rate) 
0.017 -0.116 0.428 1.000 
GRAPHIC -0.003 -0.141 0.072  
WHII 0.016 -0.123 0.30  
BWHHS Sex NA NA NA NA 
GRAPHIC  -0.135 0.103 -0.419 0.267 
WHI II  -0.12 0.119 -0.23 0.17 
BWHHS Age 0.091 -0.134 0.101 0.097 
GRAPHIC  0.282 -0.392 -0.002 0.263 
WHI II  0.15 -0.184 0.078 0.15 
BWHHS BMI 0.112 -0.180 0.096 0.095 
GRAPHIC  0.156 -0.411 0.077 0.166 
WHI II  0.088 -0.279 0.044 0.09 
BWHHS Systolic BP (corrected 
for BP medication) 
0.047 -0.107 0.117 0.111 
GRAPHIC 0.110 -0.280 0.191 0.024 
WHI II 0.095 -0.232 0.12 0.15 
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Supplementary table 3: Minor allele frequencies and missingness details for SNPs reported in table 2. 
    Whitehall II 
(N=5059) 
  BWHHS 
(N=3443) 
  GRAPHIC 
(N=2024) 
 
SNP Major 
allele 
Minor 
(coded) 
allele 
MAF N with 
genotype 
and 
phenotype 
N with 
genotype 
MAF N with 
genotype 
and 
phenotype 
N with 
genotype 
MAF N with 
genotype 
and 
phenotype 
N with 
genotype 
PR Interval            
rs7372712 C T 0.1922 4865 5011 0.1965 3002 3405 0.1787 1887 2024 
rs3807989 G A 0.4051 4880 5026 0.4090 3006 3408 0.3843 1887 2024 
QRS Duration            
rs7374540 A C 0.3977 4873 5019 0.3855 3116 3397 0.3955 1875 2024 
rs3176326 G A 0.1974 4871 5016 0.1955 3125 3409 0.2075 1875 2024 
rs10988728 A G 0.01194 4880 5026 0.01555 3125 3408 0.01416 1875 2024 
QTc Interval            
rs12039600 G A 0.1154 4879 5025 0.1153 3125 3408 0.1075 1881 2023 
rs12271931 A G 0.1377 4876 5022 0.1334 3123 3406 0.1401 1881 2024 
rs3815459 G A 0.2079 4876 5022 0.2081 3118 3400 0.2056 1881 2024 
rs2267368 A A 0.01899 4882 5028 0.01687 3125 3408 0.01709 1881 2024 
QRS Axis            
rs2132570 A A 0.2212 4880 5026 0.2235 3074 3403 0.2206 1893 2022 
rs1934968 A A 0.1128 4880 5026 0.1054 3123 3406 0.1212 1893 2023 
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Supplementary table 4: SNPs reaching array-wide significance (threshold p < 1 x 10-5) for all four phenotypes. 
SNP CHR BP coded 
allele 
non-
coded 
allele 
Gene I
2
 Fixed Effects Beta (SE) Fixed 
Effects P-
Value 
Random Effects 
Beta 
Random 
Effects 
P-Value 
QRS Axis                    
rs2132570 7 45928988 A C IGFBP3 0 2.41 (0.51) 2.89E-06 2.41 (0.51) 2.89E-06 
rs10255707 7 45921217 T C IGFBP3 0 2.42 (0.52) 3.23E-06 2.42 (0.52) 3.23E-06 
rs903889 7 45931520 C A IGFBP3 0 2.37 (0.51) 4.21E-06 2.37 (0.51) 4.21E-06 
rs1934968 10 96731807 A G CYP2C9 0 -3.17 (0.68) 3.43E-06 -3.17 (0.68) 3.43E-06 
           
QRS Duration                  
rs7374540 3 38609146 C A SCN5A 0 0.00104 (0.00018) 5.87E-09 0.00104 (0.00018) 5.87E-09 
rs9861242 3 38584338 A G SCN5A 1.57 0.00112 (0.00020) 1.20E-08 0.00112 (0.00020) 1.59E-08 
rs1805126 3 38567410 C T SCN5A 0 0.00099 (0.00018) 6.93E-08 0.00099 (0.00018) 6.93E-08 
rs11710077 3 38632903 T A SCN5A 0 -0.00113 (0.00022) 1.80E-07 -0.00113 (0.00022) 1.80E-07 
rs9833086 3 38585475 G A SCN5A 0 0.00099 (0.00019) 2.05E-07 0.00099 (0.00019) 2.05E-07 
rs12053903 3 38568397 C T SCN5A 0 0.00088 (0.00019) 1.97E-06 0.00088 (0.00019) 1.97E-06 
rs10154914 3 38607634 A T SCN5A 79.59 -0.00101 (0.00022) 4.35E-06 -0.00101 (0.00050) 4.37E-02 
rs6797133 3 38631037 A G SCN5A 0 -0.00080 (0.00018) 8.73E-06 -0.00080 (0.00018) 8.73E-06 
rs3176326 6 36755267 A G CDKN1A 0 0.00115 (0.00022) 1.41E-07 0.00115 (0.00022) 1.41E-07 
rs3176320 6 36754766 G A CDKN1A 43.04 0.00096 (0.00018) 1.94E-07 0.00100 (0.00025) 5.77E-05 
rs733590 6 36753181 C T CDKN1A 67.8 0.00091 (0.00018) 4.19E-07 0.00102 (0.00033) 1.93E-03 
rs3176323 6 36754827 C T CDKN1A 10.67 0.00093 (0.00019) 6.47E-07 0.00094 (0.00020) 2.46E-06 
rs2395655 6 36753674 G A CDKN1A 76.13 0.00089 (0.00018) 7.89E-07 0.00102 (0.00038) 6.99E-03 
rs762624 6 36753566 C A CDKN1A 61.67 0.00095 (0.00020) 1.70E-06 0.00104 (0.00033) 1.61E-03 
rs10988728 9 1.01E+08 G A TGFBR1 0 0.00352 (0.00079) 7.90E-06 0.00352 (0.00079) 7.90E-06 
           
PR Interval                    
rs7372712 3 38661196 T C SCN5A 0 0.00305 (0.00045) 8.08E-12 0.00302 (0.00049) 6.21E-10 
rs12053903 3 38568397 C T SCN5A 0 0.00216 (0.00037) 4.59E-09 0.00216 (0.00037) 4.59E-09 
rs7374540 3 38609146 C A SCN5A 0 0.00186 (0.00035) 9.50E-08 0.00186 (0.00035) 9.50E-08 
rs1805126 3 38567410 C T SCN5A 0 0.00174 (0.00037) 2.07E-06 0.00174 (0.00037) 2.07E-06 
rs7624535 3 38640206 G T SCN5A 28.77 -0.00194 (0.00042) 4.33E-06 -0.00194 (0.00042) 4.33E-06 
rs6768664 3 38659470 C A SCN5A 66.65 -0.00156 (0.00034) 4.75E-06 -0.00156 (0.00034) 4.75E-06 
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rs7373102 3 38655632 T C SCN5A 64.75 -0.00155 (0.00034) 5.32E-06 -0.00155 (0.00034) 5.32E-06 
rs3807989 7 1.16E+08 A G CAV1 67.89 0.00199 (0.00036) 1.99E-08 0.00199 (0.00036) 1.99E-08 
rs3807986 7 1.16E+08 G A CAV1 64.59 0.00193 (0.00041) 2.55E-06 0.00186 (0.00049) 1.69E-04 
rs4730743 7 1.16E+08 A T CAV2 4.1 -0.00160 (0.00035) 4.43E-06 -0.00160 (0.00035) 4.43E-06 
rs1049334 7 1.16E+08 A G CAV1 38.28 0.00295 (0.00066) 8.10E-06 0.00295 (0.00066) 8.10E-06 
           
QTc Interval                  
rs12039600 1 1.60E+08 A G NOS1AP 0 0.00476 (0.00048) 7.12E-23 0.00476 (0.00048) 7.12E-23 
rs7534004 1 1.60E+08 A G NOS1AP 15.18 0.00422 (0.00044) 7.89E-22 0.00422 (0.00044) 7.89E-22 
rs10918859 1 1.60E+08 A G NOS1AP 7.57 0.00372 (0.00040) 3.48E-20 0.00372 (0.00040) 3.48E-20 
rs10800352 1 1.60E+08 G A NOS1AP 0 0.00348 (0.00038) 6.12E-20 0.00348 (0.00038) 6.12E-20 
rs10918594 1 1.60E+08 G C NOS1AP 39.98 0.00283 (0.00033) 4.49E-18 0.00283 (0.00033) 4.49E-18 
rs7522678 1 1.60E+08 A C NOS1AP 0 0.00337 (0.00039) 5.44E-18 0.00337 (0.00039) 5.44E-18 
rs4657139 1 1.60E+08 A T NOS1AP 57.31 0.00272 (0.00032) 3.80E-17 0.00272 (0.00032) 3.80E-17 
rs6664702 1 1.60E+08 C T NOS1AP 0 0.00299 (0.00036) 1.28E-16 0.00299 (0.00036) 1.28E-16 
rs6427664 1 1.60E+08 A G NOS1AP 0 0.00302 (0.00037) 1.52E-16 0.00297 (0.00047) 2.97E-10 
rs10399680 1 1.60E+08 C T NOS1AP 0 0.00294 (0.00036) 2.20E-16 0.00285 (0.00050) 1.57E-08 
rs12733821 1 1.60E+08 G C NOS1AP 74.69 0.00260 (0.00032) 4.92E-16 0.00260 (0.00032) 4.92E-16 
rs10494366 1 1.60E+08 G T NOS1AP 72.21 0.00253 (0.00032) 1.70E-15 0.00253 (0.00032) 1.70E-15 
rs11579850 1 1.60E+08 G T NOS1AP 75.81 0.00249 (0.00032) 3.66E-15 0.00249 (0.00032) 3.66E-15 
rs1415257 1 1.60E+08 G A NOS1AP 72.34 0.00249 (0.00032) 4.10E-15 0.00249 (0.00032) 4.10E-15 
rs16847548 1 1.60E+08 C T NOS1AP 0 0.00291 (0.00037) 7.33E-15 0.00303 (0.00057) 1.34E-07 
rs1415262 1 1.60E+08 C G NOS1AP 48.33 0.00246 (0.00032) 1.07E-14 0.00246 (0.00032) 1.07E-14 
rs5000342 1 1.60E+08 G A NOS1AP 0 0.00254 (0.00033) 1.24E-14 0.00254 (0.00033) 1.24E-14 
rs10800409 1 1.61E+08 T C NOS1AP 0 0.00344 (0.00045) 1.35E-14 0.00331 (0.00063) 1.23E-07 
rs945708 1 1.60E+08 A G NOS1AP 59.52 0.00242 (0.00032) 1.50E-14 0.00242 (0.00032) 1.50E-14 
rs1932933 1 1.60E+08 A G NOS1AP 61.87 0.00241 (0.00031) 1.69E-14 0.00241 (0.00031) 1.69E-14 
rs6660701 1 1.60E+08 C G NOS1AP 53.06 0.00242 (0.00032) 2.28E-14 0.00242 (0.00032) 2.28E-14 
rs10919035 1 1.61E+08 T C NOS1AP 8.96 0.00338 (0.00045) 5.17E-14 0.00324 (0.00070) 3.32E-06 
rs4657166 1 1.60E+08 G C NOS1AP 68.68 0.00251 (0.00034) 1.26E-13 0.00251 (0.00034) 1.26E-13 
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rs4233385 1 1.60E+08 C T NOS1AP 30.08 0.00240 (0.00033) 1.63E-13 0.00240 (0.00033) 1.63E-13 
rs880296 1 1.60E+08 C G NOS1AP 45.88 0.00279 (0.00038) 1.63E-13 0.00279 (0.00038) 1.63E-13 
rs10918762 1 1.60E+08 G A NOS1AP 9.34 0.00280 (0.00038) 1.96E-13 0.00280 (0.00038) 1.96E-13 
rs4657154 1 1.60E+08 A G NOS1AP 66.61 0.00238 (0.00035) 5.03E-12 0.00238 (0.00035) 5.03E-12 
rs10800279 1 1.60E+08 C T NOS1AP 4.57 0.00229 (0.00034) 1.30E-11 0.00238 (0.00044) 7.03E-08 
rs7515045 1 1.60E+08 A C NOS1AP 34.99 0.00230 (0.00034) 2.00E-11 0.00230 (0.00034) 2.00E-11 
rs10494365 1 1.60E+08 G C NOS1AP 0 0.00313 (0.00047) 2.25E-11 0.00357 (0.00104) 5.99E-04 
rs10918602 1 1.60E+08 C T NOS1AP 2.56 0.00226 (0.00034) 2.97E-11 0.00232 (0.00041) 1.16E-08 
rs6702936 1 1.60E+08 G A NOS1AP 0 0.00223 (0.00034) 4.49E-11 0.00225 (0.00036) 3.06E-10 
rs6659759 1 1.60E+08 C T NOS1AP 12.83 0.00221 (0.00034) 5.71E-11 0.00225 (0.00038) 3.26E-09 
rs4531275 1 1.60E+08 T C NOS1AP 0 0.00202 (0.00034) 2.08E-09 0.00202 (0.00034) 2.08E-09 
rs1123217 1 1.60E+08 C G NOS1AP 0 0.00461 (0.00078) 3.16E-09 0.00380 (0.00228) 9.55E-02 
rs12128479 1 1.61E+08 G A NOS1AP 45.53 0.00316 (0.00053) 3.33E-09 0.00316 (0.00053) 3.33E-09 
rs10800366 1 1.60E+08 T C NOS1AP 4 0.00195 (0.00033) 4.75E-09 0.00195 (0.00033) 4.75E-09 
rs12026452 1 1.60E+08 A G NOS1AP 55.72 0.00260 (0.00045) 7.18E-09 0.00254 (0.00051) 6.12E-07 
rs10800397 1 1.61E+08 T C NOS1AP 0 0.00213 (0.00037) 1.14E-08 0.00213 (0.00037) 1.14E-08 
rs16857031 1 1.60E+08 G C NOS1AP 66.94 0.00248 (0.00044) 1.34E-08 0.00246 (0.00046) 8.78E-08 
rs10458392 1 1.60E+08 G T NOS1AP 3.71 0.00211 (0.00037) 1.47E-08 0.00211 (0.00037) 1.47E-08 
rs3923368 1 1.60E+08 C A NOS1AP 5.56 0.00179 (0.00032) 3.10E-08 0.00179 (0.00032) 3.10E-08 
rs10800404 1 1.61E+08 T G NOS1AP 0 0.00207 (0.00037) 3.26E-08 0.00207 (0.00037) 3.26E-08 
rs16860185 1 1.61E+08 A G NOS1AP 64.97 0.00279 (0.00052) 6.37E-08 0.00279 (0.00052) 6.37E-08 
rs7513132 1 1.60E+08 A G NOS1AP 49.67 0.00173 (0.00032) 7.03E-08 0.00173 (0.00032) 7.03E-08 
rs10918936 1 1.60E+08 A G NOS1AP 0 0.00170 (0.00032) 7.57E-08 0.00170 (0.00032) 7.57E-08 
rs7540690 1 1.60E+08 A G NOS1AP 30.88 0.00201 (0.00038) 1.11E-07 0.00210 (0.00048) 1.08E-05 
rs4657161 1 1.60E+08 G A NOS1AP 80.95 0.00165 (0.00032) 1.81E-07 0.00165 (0.00032) 1.81E-07 
rs12135795 1 1.60E+08 A G NOS1AP 79.64 0.00164 (0.00032) 1.98E-07 0.00164 (0.00032) 1.98E-07 
rs3927640 1 1.60E+08 T C NOS1AP 77.61 0.00162 (0.00032) 2.71E-07 0.00162 (0.00032) 2.71E-07 
rs10753765 1 1.60E+08 G A NOS1AP 80.06 0.00160 (0.00031) 3.86E-07 0.00160 (0.00031) 3.86E-07 
rs4557949 1 1.60E+08 A T NOS1AP 0 0.00156 (0.00031) 4.44E-07 0.00156 (0.00031) 4.44E-07 
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rs12734991 1 1.60E+08 C T NOS1AP 0 0.00157 (0.00031) 4.65E-07 0.00157 (0.00031) 4.65E-07 
rs12022557 1 1.60E+08 A G NOS1AP 19.92 0.00184 (0.00037) 5.65E-07 0.00184 (0.00037) 6.64E-07 
rs10918615 1 1.60E+08 A G NOS1AP 31.62 0.00182 (0.00037) 7.21E-07 0.00182 (0.00037) 7.21E-07 
rs4145621 1 1.60E+08 C T NOS1AP 0 0.00149 (0.00031) 1.44E-06 0.00149 (0.00031) 1.44E-06 
rs12742393 1 1.60E+08 A C NOS1AP 0 0.00150 (0.00032) 1.95E-06 0.00150 (0.00032) 1.95E-06 
rs2661818 1 1.61E+08 G C NOS1AP 37.18 0.00146 (0.00031) 2.35E-06 0.00146 (0.00031) 2.35E-06 
rs3815459 7 1.50E+08 A G KCNH2 0 0.00219 (0.00038) 9.44E-09 0.00219 (0.00038) 9.44E-09 
rs6972137 7 1.50E+08 G T KCNH2 0 0.00233 (0.00041) 1.22E-08 0.00233 (0.00041) 1.22E-08 
rs6947240 7 1.50E+08 A G KCNH2 0 -0.00179 (0.00035) 4.54E-07 -0.00181 (0.00038) 2.43E-06 
rs1805123 7 1.50E+08 C A KCNH2 0 -0.00174 (0.00035) 8.68E-07 -0.00174 (0.00035) 8.68E-07 
rs3807375 7 1.50E+08 A G KCNH2 5.3 0.00143 (0.00032) 9.49E-06 0.00143 (0.00032) 9.49E-06 
rs12271931 11 2435095 G A KCNQ1 36.93 -0.00292 (0.00044) 3.17E-11 -0.00301 (0.00074) 4.36E-05 
rs2267368 22 36895155 A G PLA2G6 72.98 -0.00499 (0.00112) 7.80E-06 -0.00499 (0.00112) 7.80E-06 
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Supplementary Figures  
 
Supplementary Figure 1: Phenotype distributions in the three cohorts 
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Supplementary Figure 2: QQ plots for each trait  
BWHHS: 
 
 
 
 
 
GRAPHIC: 
 
 
 
 
 
WHII 
 
 
 
 
 at GLASGOW UNIV LIB on February 19, 2013circgenetics.ahajournals.orgDownloaded from 
Gaunt et al Supplementary Information        p.25/34 
Supplementary Figure 3: eQTL plots illustrating differential expression of (A) CAV1 by rs3807989 genotype, (B) IGFBP3 by rs2132570 genotype, and (C) 
CYP2C9 by rs1934968 genotype. 
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Supplementary Figure 4: Illustrative example of modelling the effects on QT interval and QRS duration for a given change of INa. In both cases as the % INa 
reduction increases (x-axis) the predicted QT interval increases (y-axis). 
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Supplementary Figure 5: SNP associations with all four traits across the SCN5A region illustrated in the UCSC genome browser (http://genome.ucsc.edu/). 
Genomic location is represented on the horizontal axis, pairwise linkage disequilibrium illustrated by red in the triangular heat map (bottom) and SNP 
associations by the height of bars in the four charts (top) 
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Supplementary Figure 6: SNP associations with all four traits across the NOS1AP region illustrated in the UCSC genome browser (http://genome.ucsc.edu/). 
Genomic location is represented on the horizontal axis, pairwise linkage disequilibrium illustrated by red in the triangular heat map (bottom) and SNP 
associations by the height of bars in the four charts (top) 
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Supplementary Figure 7: Linkage disequilibrium block around KCNH2 and NOS3 as presented in the HapMap browser (www.hapmap.org) with genomic 
location on the horizontal axis and pairwise linkage disequilibrium illustrated by red in the triangular heat map (bottom). 
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